Allografts are human donor tissues (e.g. bone) processed for use in orthopaedic, dental and trauma procedures (e.g. spinal, pelvic and fracture non-union).

These products can be cleaned and processed via methods based on eCOO Technology. Subsequent sterilisation of these products can be achieved again by eCOO Technology-based sterilisation or other conventional methods.

eTiss allograft products include eTiss� bone void fillers, ideally suited for a multitude of orthopaedic applications and exhibiting excellent osteoconductivity, eTiss Demineralised Bone Matrix (DBM), typically used in complex fractures and spinal fusion and eTiss soft tissue allografts (e.g. tendons), used as a replacement of ruptured tendons after sports-related injuries and particularly benefiting from the retained tensile strength.
eTiss allografts can, in the near future, be further enhanced by EMCM’s eCOO Plus technology, enabling controlled release of API’s.

Main advantages include:

  • Lower risk of transmitting diseases than the products currently available
  • Retain of mechanical properties of the eTiss allografts
  • Excellent osteoconductive and inductive properties
  • SAL 6 sterility
  • Controlled delivery of APIs

For scientific data, please click here.

Most of the products developed at EMCM under the eTiss family are classified as Human Tissue (Allografts), as per the EU directives, and are available for distribution in most European countries:


The above product portfolio is provided to bone and tissue banks & medtech companies alike, either as a finished product or as a contracted service.

EMCM is currently in the process of registration of its techniques and products in Europe, the Middel-East and Latin/South America.  

Due to host material, scientific and technical limitations, all advantages of the eCOO Technology platform may not be applicable to each product under eTiss, eColl & eNova products.